Linda Mileshkin

Universitat Jaume I — Spain

Medicine · Health Sciences

71h-index31.9kcitations554works6.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Endometrial and Cervical Cancer Treatments(128), Ovarian cancer diagnosis and treatment(114), Cancer Genomics and Diagnostics(79), Cancer Diagnosis and Treatment(52), PARP inhibition in cancer therapy(41)

Publications504 total

Survival and patterns of failure in small cell neuroendocrine carcinoma of the cervix treated with definitive chemoradiotherapy
International Journal of Gynecological Cancer·2025Open Access
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial
Obstetrical & Gynecological Survey·2025
762MO Clinical whole genome and transcriptome sequencing for cancer of unknown primary: An Australian prospective observational study
Annals of Oncology·2025
Bowel obstruction in advanced malignancies: An evaluation of patient outcomes at a tertiary cancer centre
Malignancy Spectrum·2025Open Access
EXERCISE THERAPY ADDED TO FIRST-LINE CHEMOTHERAPY FOR OVARIAN CANCER: EFFECTS ON PROGRESSION-FREE SURVIVAL AND PHYSICAL WELLBEING IN THE RANDOMISED, PHASE 3 ECHO TRIAL (ANZGOG1304/CTC121)
International Journal of Gynecological Cancer·2025
EXPLORING TRANSCRIPTIONAL SUBTYPES AND IMMUNE MARKERS IN BEACON; PHASE II STUDY OF ATEZOLIZUMAB, BEVACIZUMAB, COBIMETINIB IN PLATINUM RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER
International Journal of Gynecological Cancer·2025
PHASE 3 ROSELLA (GOG-3073, ENGOT-OV72) TRIAL OF RELACORILANT + NAB-PACLITAXEL VS NAB-PACLITAXEL IN PLATINUM-RESISTANT OVARIAN CANCER: PRIMARY RESULTS AND OUTCOMES IN OLDER PATIENTS
International Journal of Gynecological Cancer·2025
Impact of age and comorbidity on safety outcomes in phase 1 trial participants for metastatic solid malignancies
Journal of Geriatric Oncology·2025Open Access
Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial
Obstetrical & Gynecological Survey·2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial
The Lancet Oncology·2025· 12 citedOpen Access
Safety and preliminary efficacy of puxitatug samrotecan (AZD8205) in patients with endometrial cancer: A first-in-human phase I/IIa study
Gynecologic Oncology·2025· 1 cited
LBA45 ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + nab-paclitaxel in the subgroup of patients with platinum-resistant ovarian cancer (PROC) previously exposed to a PARP inhibitor
Annals of Oncology·2025· 1 citedOpen Access
1172P The relationship between patient-reported outcomes and clinician-rated toxicity in participants with locally advanced cervix cancer in the OUTBACK trial
Annals of Oncology·2025
1065MO First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer
Annals of Oncology·2025
CN88 A phase II randomized trial of nurse led telehealth follow-up including patient reported outcomes using the MOST-S26 (measure of ovarian symptoms and treatment concerns) versus routine clinic based or telehealth follow-up, after completion of chemotherapy in patients with ovarian cancer
Annals of Oncology·2025
1089P Telling it as it is: Quality of life outcomes associated with maintenance olaparib and cediranib following a response to chemotherapy in relapsed platinum-sensitive ovarian cancer
Annals of Oncology·2025
118P Impact of age and comorbidity on safety outcomes in phase I trials participants for metastatic solid malignancies
ESMO Open·2025Open Access
115O PROPOSE: Predicting phase I trial fitness using patient-reported outcomes and a clinician-completed prognostic index
ESMO Open·2025Open Access
Cancer of the corpus uteri: A 2025 update
International Journal of Gynecology & Obstetrics·2025· 8 citedOpen Access
Erratum to ‘Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma’ [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644]
International Journal of Gynecological Cancer·2025Open Access
page 1 of 26Next →

Frequent Co-authors

Carien L. Creutzberg(16), Melanie Powell(15), Vincent T.H.B.M. Smit(14), Stephanie M. de Boer(13), Hans W. Nijman(13), Remi A. Nout(13), Tjalling Bosse(13), Alexandra Léary(12), Naveena Singh(10), Michael Friedländer(9), David D.L. Bowtell(9), Helen Mackay(9), Nanda Horeweg(9), Jonathan A. Ledermann(8), Diane Provencher(8), Anthony Fyles(8), Emma J. Crosbie(8), Jan Pyman(7), Pearly Khaw(7), Richard T. Penson(6)